[go: up one dir, main page]

MX2012002427A - Anticuerpos anticina que se unen a quimiocinas cc multiples. - Google Patents

Anticuerpos anticina que se unen a quimiocinas cc multiples.

Info

Publication number
MX2012002427A
MX2012002427A MX2012002427A MX2012002427A MX2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A
Authority
MX
Mexico
Prior art keywords
chemokines
antikine
bind
antikine antibodies
antibodies
Prior art date
Application number
MX2012002427A
Other languages
English (en)
Inventor
Dan Allison
Carol Raport
Original Assignee
Vlst Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlst Corp filed Critical Vlst Corp
Publication of MX2012002427A publication Critical patent/MX2012002427A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe un anticuerpo anticina que se une a dos, tres, cuatro, cinco o más quimiocinas CC, tales como RANTES/CCL5, MIP-1a/CCL3, MIP-1ß/CCL4, o MCP-1/CCL2. También se describen métodos para maduración de afinidad y humanización de anticuerpos anticina así como la producción de líneas de célula de hibridoma produciendo anticuerpos anticina a través de inmunización secuencial.
MX2012002427A 2009-08-28 2010-08-27 Anticuerpos anticina que se unen a quimiocinas cc multiples. MX2012002427A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23801509P 2009-08-28 2009-08-28
PCT/US2010/047004 WO2011025962A1 (en) 2009-08-28 2010-08-27 Antikine antibodies that bind to multiple cc chemokines

Publications (1)

Publication Number Publication Date
MX2012002427A true MX2012002427A (es) 2012-08-03

Family

ID=43628404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002427A MX2012002427A (es) 2009-08-28 2010-08-27 Anticuerpos anticina que se unen a quimiocinas cc multiples.

Country Status (18)

Country Link
US (3) US8313747B2 (es)
EP (1) EP2470671B1 (es)
JP (2) JP6109571B2 (es)
KR (1) KR101778813B1 (es)
CN (1) CN102782148B (es)
AU (1) AU2010286516B2 (es)
BR (1) BR112012004387A2 (es)
CA (1) CA2771781C (es)
DK (1) DK2470671T3 (es)
ES (1) ES2531561T3 (es)
HR (1) HRP20150162T1 (es)
IN (1) IN2012DN01769A (es)
MX (1) MX2012002427A (es)
PL (1) PL2470671T3 (es)
PT (1) PT2470671E (es)
SI (1) SI2470671T1 (es)
SM (1) SMT201500011B (es)
WO (1) WO2011025962A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010286516B2 (en) * 2009-08-28 2016-10-06 Regeneron Pharmaceuticals, Inc. Antikine antibodies that bind to multiple CC chemokines
CN103857421B (zh) * 2011-06-13 2017-09-22 Tla指标免疫疗法公司 治疗癌症的方法和在其中使用的结合试剂
WO2013033206A2 (en) * 2011-08-29 2013-03-07 University Of Rochester Compositions and methods for inhibiting ccl3
WO2013036290A1 (en) * 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
KR102134088B1 (ko) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
JO3580B1 (ar) * 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
EP2999484B1 (en) 2013-05-23 2019-09-11 Shire Human Genetic Therapies, Inc. Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma
JP6220222B2 (ja) * 2013-10-28 2017-10-25 シスメックス株式会社 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品
NZ720769A (en) * 2013-12-09 2022-10-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
EP3110446B1 (en) 2014-02-28 2021-12-01 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases
JP6553075B2 (ja) * 2014-03-04 2019-08-07 ケモマブ リミテッドＣｈｅｍｏｍＡｂ Ｌｔｄ． さらなるｃｃｒ３−結合ケモカインを認識する抗エオタキシン−２抗体
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
TWI566780B (zh) * 2014-10-24 2017-01-21 國立陽明大學 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途
LT3230320T (lt) * 2014-12-09 2021-01-11 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
EP3310385A4 (en) 2015-06-17 2018-12-19 Allakos Inc. Methods and compositions for treating fibrotic diseases
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018159787A1 (ja) * 2017-03-01 2018-09-07 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
US11655306B2 (en) * 2017-04-05 2023-05-23 Korea Research Institute Of Bioscience And Biotechnology NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
AU2018261887A1 (en) 2017-05-05 2019-12-05 Allakos Inc. Methods and compositions for treating allergic ocular diseases
WO2019037067A1 (zh) * 2017-08-25 2019-02-28 法玛科技顾问股份有限公司 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途
CN111801353B (zh) * 2017-10-13 2024-09-17 A&G药品公司 针对前列腺素f2受体抑制剂的单克隆抗体和缀合物及其用途
EP3732196A4 (en) * 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
WO2019165397A1 (en) * 2018-02-26 2019-08-29 Cornell University Quantitative biomarkers of ehv-1 susceptibility and protection
KR20210039985A (ko) * 2018-05-11 2021-04-12 헬시언 테라퓨틱스 인코포레이티드 Gasp-1 과립을 표적으로 하는 결합 단백질 및 키메라 항원 수용체 t 세포, 및 이의 용도
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN110117329B (zh) * 2019-04-03 2020-12-08 河北浓孚雨生物科技有限公司 包含趋化因子与结合伴侣的融合多肽及其用途
WO2021003284A1 (en) * 2019-07-02 2021-01-07 Astute Medical, Inc Antibodies and assays for ccl14
KR102489282B1 (ko) * 2019-07-02 2023-01-17 고려대학교 산학협력단 Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN113893331B (zh) * 2020-07-06 2024-11-26 中国农业科学院特产研究所 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用
US20230242623A1 (en) * 2020-07-08 2023-08-03 Georgia Tech Research Corporation Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
IL302078A (en) * 2020-10-16 2023-06-01 Lanova Medicines Ltd Anti-ccr8 monoclonal antibodies and uses thereof
CN115598111B (zh) * 2021-07-08 2025-03-25 南京大学 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法
CN114990073A (zh) * 2022-05-27 2022-09-02 河南农业大学 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
NZ542784A (en) 2002-08-19 2008-07-31 Astrazeneca Ab Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
AU2003293096B9 (en) 2002-11-27 2011-09-29 Biogen Ma Inc. Humanized antibodies against monocyte chemotactic proteins
ES2321122T3 (es) 2004-12-21 2009-06-02 Laboratoires Serono S.A. Antagonistas de quimiocinas cc.
US8012474B2 (en) 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
AU2010286516B2 (en) * 2009-08-28 2016-10-06 Regeneron Pharmaceuticals, Inc. Antikine antibodies that bind to multiple CC chemokines

Also Published As

Publication number Publication date
EP2470671A1 (en) 2012-07-04
HRP20150162T1 (hr) 2015-05-08
BR112012004387A2 (pt) 2015-09-08
DK2470671T3 (en) 2015-02-09
US20130108640A1 (en) 2013-05-02
ES2531561T3 (es) 2015-03-17
CA2771781A1 (en) 2011-03-03
CN102782148B (zh) 2016-04-20
IN2012DN01769A (es) 2015-06-05
US20150166647A1 (en) 2015-06-18
US8313747B2 (en) 2012-11-20
JP2013503192A (ja) 2013-01-31
PL2470671T3 (pl) 2015-05-29
WO2011025962A1 (en) 2011-03-03
AU2010286516B2 (en) 2016-10-06
AU2010286516A1 (en) 2012-03-08
JP6109571B2 (ja) 2017-04-05
EP2470671B1 (en) 2014-12-24
KR20120091013A (ko) 2012-08-17
CN102782148A (zh) 2012-11-14
JP2016135783A (ja) 2016-07-28
US9005617B2 (en) 2015-04-14
SMT201500011B (it) 2015-03-05
KR101778813B1 (ko) 2017-09-14
EP2470671A4 (en) 2013-04-03
CA2771781C (en) 2019-01-15
PT2470671E (pt) 2015-02-05
AU2010286516A2 (en) 2012-06-14
RU2012111820A (ru) 2013-10-10
US20110059107A1 (en) 2011-03-10
SI2470671T1 (sl) 2015-04-30

Similar Documents

Publication Publication Date Title
MX2012002427A (es) Anticuerpos anticina que se unen a quimiocinas cc multiples.
TN2014000107A1 (en) Anti-aplhabetatcr antibody
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MX362705B (es) Anticuerpos monoclonales multiespecíficos.
WO2015173756A3 (en) Bispecific antibodies with engineered ch1-cl interfaces
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
CR20190009A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso.
MX337684B (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f.
TN2013000292A1 (en) Antibody molecules which bind il-17a and il-17f
MX2012000841A (es) Optimizacion de la produccion de anticuerpos.
WO2013177101A3 (en) Il-17a/f il-23 bispecific antibodies and their uses
WO2009130459A3 (en) Epitopes of il-17a and il-17f and antibodies specific thereto
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
JOP20200106A1 (ar) جسم مضاد أحادي النسيلة مضاد لـ il-5r?
WO2013186630A3 (en) Humanized antibodies to ca215
WO2012122513A3 (en) Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
CY1116009T1 (el) Αντισωματα αντικινες που προσδενονται σε πολλαπλες χημειοκινες cc
AU2016219622A1 (en) Heterodimeric antibody FC-containing proteins and methods for production thereof
TN2013000186A1 (en) Anti-il-23 antibodies
EA201990353A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ СПОСОБНОСТЬЮ НЕЙТРАЛИЗОВАТЬ ГЛАВНЫЕ ЭКЗОТОКСИНЫ TcdA И TcdB Clostridium difficile

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: REGENERON PHARMACEUTICALS, INC.

FG Grant or registration